Medtronic plc
NYSE•MDT
CEO: Mr. Geoffrey Straub Martha
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1973-05-02
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
Contact Information
Market Cap
$124.16B
P/E (TTM)
26.9
36.3
Dividend Yield
2.9%
52W High
$106.33
52W Low
$79.55
52W Range
Rank25Top 11.9%
5.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$9.02B+0.00%
4-Quarter Trend
EPS
$0.89+0.00%
4-Quarter Trend
FCF
$2.30B+0.00%
4-Quarter Trend
2026 Q3 Earnings Highlights
Key Highlights
Nine Month Net Sales Growth Total net sales reached $26.56B for nine months, marking an 8% increase driven by growth and currency fluctuations.
Strong Operating Cash Flow Operating cash flow provided $4.76B, increasing $241M due to higher customer cash collections this reporting period.
Cardiovascular Segment Performance Cardiovascular net sales grew 11% to $10.18B for nine months, driven by strong product adoption across divisions.
Diabetes Sales Momentum Diabetes segment net sales increased 12% to $2.27B for nine months, fueled by international MiniMed 780G adoption.
Risk Factors
Increased Restructuring Costs Total restructuring costs rose to $251M for nine months, reflecting MiniMed separation planning and other associated actions.
Macroeconomic Tariff Headwinds Estimated pre-tax net tariff impact for fiscal year 2026 is $185M, posing risk to cost structure and financial performance.
Major Litigation Award Applied Medical jury awarded $382M in damages, subject to trebling, creating significant potential liability uncertainty.
Rising Long-Term Debt Long-term debt increased to $27.88B as of January 23, 2026, driven by new Euro-denominated Senior Notes issuance.
Outlook
Diabetes Separation Timeline Diabetes business separation into MiniMed Group expected completion within 18 months following the May 2025 announcement.
CathWorks Acquisition Planned Intention announced to acquire CathWorks for up to $585M, expanding Coronary & Peripheral Vascular division capabilities.
Pipeline Commercialization Focus Focus remains on meeting demand, obtaining regulatory approvals, and commercializing pipeline products like Affera Sphere-360.
Peer Comparison
Revenue (TTM)
$402.07B
$397.96B
$75.60B
Gross Margin (Latest Quarter)
85.6%
78.3%
74.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PFE | $151.13B | 19.4 | 8.7% | 32.4% |
| SYK | $147.18B | 45.3 | 15.0% | 31.1% |
| DHR | $144.26B | 39.9 | 7.0% | 22.1% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.3%
Moderate Growth
4Q Net Income CAGR
2.6%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 20, 2026
EPS:$1.67
|Revenue:$9.65B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data